ArticleBMC infectious diseases2025
Incidence of dynamic seroconversion in subjects received the first dose of the SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa, Democratic Republic of Congo: prospective cohort study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMass vaccination efforts worldwide have reduced the incidence of COVID-19, but despite this reduction, seroconversion studies in sub-Saharan Africa are limited. The aim of this study is to assess the incidence of seroconversion in subjects who received the first dose of SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa.
methodsThis was a prospective study recruiting 918 subjects vaccinated at the Cliniques Universitaires de Kinshasa between 19 April and 14 August 2021. Sociodemographic, haematological, biochemical and serological data were collected. Cox proportional hazards were used to identify predictors of seroconversion with a threshold of p < 0.05.
resultsOf the 918 vaccinated individuals, 69.3% were men with a mean age of 47.4 ± 16.0 years. The incidence of seroconversion at last follow-up was 3.00 per 100 P-D. Patients receiving Pfizer (aRR: 3.19; 95% CI: 2.62-3.88) and Modern (aRR: 1.91; 95% CI: 1.60-2.29) vaccines, men (aRR: 2.03; 95% CI: 1.89-3.20), those with comorbidities (aRR: 2.38; 95% CI: 1.89-3.21); subjects with normal creatinine (aRR: 2.08; 95% CI: 1.88-3.32) and normal ALT (aRR: 3.04; 95% CI: 1.89-4.22) were the factors independently predicting seroconversion.
conclusionThe vaccines used had conferred significant immunity on subjects upon receipt of the first dose. This immunity appears to be greater when using the mRNA vaccine than when using the inactivated vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.